Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05611567
Other study ID # DD/CTMD2/019/2019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 20, 2020
Est. completion date September 1, 2022

Study information

Verified date November 2022
Source Emirates Health Services (EHS)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary Obesity Surgery Endoluminal 2.0, or POSE 2.0, (USGI Medical, San Clemente, CA) creates full-thickness plications of gastric tissue endoscopically to shorten the stomach and narrow its aperture for weight loss in patients with obesity. Adults with obesity and non-alcoholic NAFLD were allocated based on preference and motivation to undergo the POSE 2.0 procedure with lifestyle modification or lifestyle modification alone to study the impact of the POSE2.0 procedures on NAFLD parameters and metabolic profile. Co-primary endpoints included improvement in controlled attenuation parameter (CAP) and resolution of hepatic steatosis at 12 months. Secondary endpoints included total body weight loss (TBWL), change in serum measures of hepatic steatosis and insulin resistance, and device safety.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date September 1, 2022
Est. primary completion date March 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Subject agrees to be compliant with study requirements and adhere to post-operative dietary & exercise recommendations for the duration of the study. 3. Subjects age >=18 years old. 4. Hepatic steatosis from NAFLD, as defined by a controlled attenuation parameter = 280 dB/m without alternate cause of liver disease measured by a Fibroscan XL. 5. Body Mass Index = 30kg/m2 6. If female, be either post-menopausal, surgically sterile, or agree to practice birth control during year of study and have negative serum HCG at screening/baseline. 7. Absence of current severe systemic disease (including, but not limited to: coronary artery disease, chronic obstructive pulmonary disease, congestive heart failure, cancer, and chronic renal disease). 8. Agrees not to undergo any additional weight loss interventional procedures or liposuction for 12 months following study enrollment. 9. Have not taken any prescription or over-the-counter weight loss medications OR those that can suppress appetite/induce weight loss for at least 6 months and agrees not to utilize for 12 months following study enrollment (including all stimulant medication). 10. Subjects must be willing to possibly forego any future weight loss procedures (i.e. Vertical Sleeve Gastrectomy) given the unknown long-term effects. 11. Residing within a reasonable distance from the Investigator's treating office (~50 miles) and willing and able to travel to the Investigator's office to complete all routine follow-up visits. Exclusion Criteria: 1. History of (or intra-operative evidence of) prior bariatric, gastric or esophageal surgery. 2. Esophageal stricture or other anatomy and/or condition that could preclude passage of endoluminal instruments or procedure execution. 3. Moderate gastro-esophageal reflux disease (GERD), defined as symptoms that cause subject severe discomfort, compromise performance of daily activities, and/or condition is not entirely controlled with drug therapy. 4. Large hiatal hernia (>3 cm) by history or as determined by pre-enrollment endoscopy. 5. Pancreatic insufficiency/disease. 6. History of gastroparesis or symptoms that would be suggestive of gastroparesis or generalized dysmotility (e.g. esophago-gastric motility issues and lower esophageal sphincter abnormalities). 7. Pregnancy or plans of pregnancy in the next 12 months. 8. History of a known diagnosis or pre-existing symptom of rheumatoid arthritis, scleroderma, system lupus, or other autoimmune connective tissue disorder. 9. Immunosuppressive medications or systemic steroids (i.e., oral prednisone) within 6 months of Visit 1. Intranasal/inhaled steroids are acceptable. 10. Unable or unwilling to avoid use of aspirin and/or non-steroidal anti-inflammatory drugs (NSAIDs), or other medications known to be gastric irritants beginning two weeks prior to enrollment and throughout the entire study. 11. History of inflammatory disease of the GI tract; coagulation disorders; hepatic insufficiency or cirrhosis. 12. Active gastric erosion, lesion, or gastric/duodenal ulcer. 13. History of or current platelet or coagulation dysfunction, such as hemophilia. 14. History or present use of insulin or insulin derivatives for treatment of diabetes. 15. Type II Diabetes Mellitus (as defined by HgbA1c >6.5%) for greater than 11 years at the time of enrollment. 16. If smoker, plans to quit smoking in the year after enrollment. 17. Portal hypertension and/or varices. 18. Patient has a history of drug or alcohol abuse or positive at screening for drugs of abuse. 19. Present or history of psychosis, bipolar disease, or obsessive-compulsive disorder after pre-enrollment history and medical /psychological assessment. 20. Beck Depression Inventory (Short) Score = 12 and/or uncontrolled depression after pre-enrollment psychological and medical assessment. 1 21. Patient score >2 in any of the 9 identified symptoms on the Gastroparesis Cardinal Symptom Index (GCSI) 22. Non-ambulatory or has significant impairment of mobility (i.e. cannot ambulate for 30 minutes). 23. Known hormonal or genetic cause for obesity including untreated hypothyroidism (TSH >5.0 U/ml). 24. Participating in another clinical study. 25. Subjects with a personal history of allergic/anaphylactic reactions including hypersensitivity to the drugs or materials that will be utilized in the study procedure. 26. Physician's assessment that the subject is not an appropriate candidate. -

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
POSE2.0 procedure
The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)
Behavioral:
Life style and behavioral intervention
The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.

Locations

Country Name City State
United Arab Emirates Obaidulla Hospital, Emirates Health Services, Ministry of Health, United Arab Emirates Ras Al Khaimah

Sponsors (2)

Lead Sponsor Collaborator
Emirates Health Services (EHS) Mayo Clinic

Country where clinical trial is conducted

United Arab Emirates, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in total body weight loss (TBWL) in each arm 12 months
Primary Change in controlled attenuation parameter (CAP) Measured by Fibroscan XL 12 months
Primary Change in liver stiffness Measured by Fibroscan XL 12 months
Secondary Percent resolution of hepatic steatosis at 12 months Measured by fibroscan XL 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2